ArticlePharmacology research & perspectives2026
Excessive Apixaban Concentrations in a Bleeding Patient Treated With Pharmacological Reversal and Extracorporal Removal-A Case Report.
Article in Pharmacology research & perspectives, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In trauma, even therapeutic apixaban levels can significantly exacerbate bleeding. In cases of overdose, the risk of prolonged, life-threatening hemorrhage increases substantially, necessitating targeted interventions, such as pharmacological reversal agents. Rapid identification of elevated anticoagulant levels is crucial to initiate specific countermeasures and limit blood loss, and point-of-care testing may facilitate timely treatment. In our case of an extreme overdose of apixaban (max 5664.24 ng/mL, first report of such high amount) has resulted in serious and life-threatening clinical symptoms due to sustained multiple injuries. It is still a debate which therapies prove the most efficacious, whereby the vast surplus of apixaban and the short half-life of andexanet alfa must be considered. This case, in which high apixaban concentration persisted, might help to shed light on these issues.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.